Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 101kWORD 24k
1 June 2018
E-001467/2018(ASW)
Answer given by Ms Bieńkowska on behalf of the Commission
Question reference: E-001467/2018

The Commission has no current plans to submit a new proposal for the revision of Directive 89/105/EEC. It is now working to ensure the appropriate implementation of the existing Directive by the Member States.

The Commission has no current plans to develop common cost accounting and pricing methods for medicines in the European market.

However, the Commission is supporting improved exchange of information among Member States and promoting their cooperation on a voluntary basis for example through the Network of competent authorities responsible for pricing and reimbursement (CAPR), by supporting a European medicine price data base(1) focusing on the appropriate use of current data sets of product prices and implementing effective application of reference pricing to participating Member States and by supporting a Project on Sustainable Access to Innovative Therapies(2).

(1)Euripid project : http://ec.europa.eu/chafea/news/news492.html
(2)Organisation for Economic Cooperation and Development (OECD) Project on Sustainable Access to Innovative Therapies : http://www.oecd.org/els/health-systems/pharmaceuticals.htm

Last updated: 5 June 2018Legal notice